Daniel M. Skovronsky

Affiliations: 
Founder and CEO Avid Radiopharmaceuticals, Philadelphia, PA, United States 
Website:
http://www.avidrp.com/aboutus/aboutus_management.html#daniel
Google:
"Daniel Skovronsky"
Mean distance: 15.62 (cluster 24)
 
SNBCP
Cross-listing: Neuropathology Tree - Chemistry Tree

Parents

Sign in to add mentor
Nicholas K. Gonatas post-doc Penn
 (Early 1990's)
Virginia Man-Yee Lee post-doc Penn
 (Early 1990's)
John Q. Trojanowski post-doc Penn
 (Early 1990's)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Grundman M, Johnson KA, Lu M, et al. (2016) Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. Dementia and Geriatric Cognitive Disorders. 41: 80-92
Joshi AD, Pontecorvo MJ, Skovronsky DM, et al. (2015) A semi-automated method for quantification of florbetapir F 18 PET images. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Klunk WE, Koeppe RA, Price JC, et al. (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 1-15.e1-4
Tateno A, Sakayori T, Kawashima Y, et al. (2015) Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. International Journal of Geriatric Psychiatry. 30: 505-13
Siderowf A, Pontecorvo MJ, Shill HA, et al. (2014) PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. Bmc Neurology. 14: 79
Doraiswamy PM, Sperling RA, Johnson K, et al. (2014) Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry. 19: 1044-51
Joshi AD, Pontecorvo MJ, Adler L, et al. (2014) Radiation dosimetry of florbetapir F 18. Ejnmmi Research. 4: 4
Dugger BN, Clark CM, Serrano G, et al. (2014) Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. Journal of Neuropathology and Experimental Neurology. 73: 72-80
Rosenberg PB, Wong DF, Edell SL, et al. (2013) Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 272-8
Johnson KA, Sperling RA, Gidicsin CM, et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: S72-83
See more...